PROTAC BRD4 Degrader-49
BRD4 degrader-8 is a BRD4-targeting degrader. BRD4 degrader-8 induces degradation of BRD4 protein via the ubiquitin-proteasome pathway. BRD4 degrader-8 can be used for the research of hematologic tumors, gastrointestinal stromal tumors, histiocytic lymphoma, non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, pancreatic cancer, breast cancer, prostate cancer, liver cancer, skin cancer, epithelial cell carcinoma, colorectal cancer, kidney cancer, gastric cancer, head and neck cancer, nasopharyngeal cancer.
(Pink: BRD4 ligand (HY-185884); Blue: VHL ligand (HY-125845); Black: linker).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 3115940-40-1
- Formule: C53H67N9O6S2
- Masse moléculaire:990.29
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform PROTACs
More
Activité biologique
Description
IC50 & Target
[1]|
BRD4 |
In Vitro
BRD4 degrader-8 (compound 12) (10 nM; 24 h) induces 81% degradation of BRD4 protein in PC-3 cells when administered at 10 nM for 24 hours[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:PC-3 human prostate cancer cells
-
Concentration:10 nM
-
Incubation Time:24 h
-
Result:Reduced BRD4 protein level by 81%.
Chemical Information
-
CAS No. 3115940-40-1
-
Masse moléculaire 990.29
-
Formule C53H67N9O6S2
-
SMILES
CC1=C(SC2=C1C(C3=CC=C(C=C3)OCCCCCC(N[C@@H](C(C)(C)C)C(N4[C@]([H])(C(N[C@@H](CCCCCCN5)C6=CC=C(C=C6)C7=C(C)N=CS7)=O)C[C@@H](O)C4)=O)=O)=N[C@]([H])(C8=NN=C(N28)C)CC5=O)C
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
PROTAC BRD4 Degrader-49 Related Classifications
HY-185854 Related Classifications
Powered by Bioz
Keywords